Additive effects of resveratrol and doxorubicin on bladder cancer cells.
Nenhuma Miniatura disponível
Data
2022
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
The treatment of bladder cancer remains a challenge in
clinical practice. Different chemotherapeutic protocols
can be used; however, it is common to observe tumor
recurrence and secondary effects that result in toxicity.
Doxorubicin (DOX), one of the most effective anticancer
agents used to treat bladder cancer, can cause chronic
cardiotoxicity, limiting its use in clinical practice.
Resveratrol (RES), a natural product with potential
antitumor activity against bladder cancer, is associated
with rapid metabolism and low bioavailability and needs to
be combined with chemotherapeutic drugs to improve its
use. Our study aimed to assess the therapeutic effect of a
low concentration of DOX (2µM) in combination with RES
(150, 200 and 250µM) on two bladder cancer cell lines.
We investigated the mechanism of interaction between
the drugs by performing cytotoxicity, clonogenic, oxidative
stress, cell migration, cell morphology and nuclear division
index (NDI) assays. Cytotoxicity evaluation revealed an
additive interaction between RES and DOX for both cell
lines. Additionally, the results of cell colony formation,
oxidative stress, cell migration, cell morphology and NDI
assays showed that a combination of DOX and RES was
more effective than RES or DOX alone. In conclusion,
a low concentration of DOX combined with RES could
potentiate the antitumor effects of the drugs on bladder
cancer cells, thus overcoming the secondary effects
caused by DOX and the low bioavailability of resveratrol.
Descrição
Palavras-chave
Cell death, Reactive oxygen species
Citação
SOARES, L. B. M. et al. Additive effects of resveratrol and doxorubicin on bladder cancer cells. Anti-Cancer Drugs, v. 33, n. 1, p. e389–e397, 2022. Disponível em: <https://journals.lww.com/anti-cancerdrugs/Fulltext/2022/01000/Additive_effects_of_resveratrol_and_doxorubicin_on.54.aspx>. Acesso em: 11 out. 2022.